{"transactions":[{"id":820387,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T16:06:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":33833,"derivative":{"exercise_price":10.42,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0002050422-26-000012","document":"form4-04022026_080443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000012/form4-04022026_080443.xml","form_type":"4"}},{"id":820386,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-04-02T16:06:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":30.3367,"value":9101.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-26-000012","document":"form4-04022026_080443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000012/form4-04022026_080443.xml","form_type":"4"}},{"id":820385,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-04-02T16:06:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":29.3227,"value":64509.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":13265,"source":{"system":"sec-edgar","filing":"0002050422-26-000012","document":"form4-04022026_080443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000012/form4-04022026_080443.xml","form_type":"4"}},{"id":820384,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-04-02T16:06:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":10.42,"value":26050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15465,"source":{"system":"sec-edgar","filing":"0002050422-26-000012","document":"form4-04022026_080443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000012/form4-04022026_080443.xml","form_type":"4"}},{"id":868983,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":16000,"derivative":{"underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":868982,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":32000,"derivative":{"exercise_price":45.61,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":868981,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":36333,"derivative":{"exercise_price":10.42,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":868980,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":45.4694,"value":168236.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.99 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":868979,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":44.4414,"value":57773.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":16665,"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":868978,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-03-03T16:20:41.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.42,"value":52100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17965,"source":{"system":"sec-edgar","filing":"0002050422-26-000010","document":"form4-03032026_090334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000010/form4-03032026_090334.xml","form_type":"4"}},{"id":919746,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":41333,"derivative":{"exercise_price":10.42,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":156},"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919745,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":4844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026."}],"balance_after":3025,"derivative":{"exercise_price":10.42,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":4844},"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919744,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":736,"price":46.6323,"value":34321.3728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.365 to $47.23 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919743,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":4064,"price":46.0305,"value":187067.952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.345 to $46.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":13701,"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919742,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":44.15,"value":8830.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17765,"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919741,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":156,"price":10.42,"value":1625.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17965,"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":919740,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T16:23:11.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":4844,"price":10.42,"value":50474.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17809,"source":{"system":"sec-edgar","filing":"0002050422-26-000008","document":"form4-02042026_090208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000008/form4-02042026_090208.xml","form_type":"4"}},{"id":931302,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T16:10:37.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":false,"shares":2503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":7869,"derivative":{"exercise_price":10.42,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":2503},"source":{"system":"sec-edgar","filing":"0002050422-26-000005","document":"form4-01262026_090133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000005/form4-01262026_090133.xml","form_type":"4"}},{"id":931301,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T16:10:37.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":false,"shares":2497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":486,"derivative":{"exercise_price":10.42,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":2497},"source":{"system":"sec-edgar","filing":"0002050422-26-000005","document":"form4-01262026_090133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000005/form4-01262026_090133.xml","form_type":"4"}},{"id":931300,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-26T16:10:37.000Z","date":"2026-01-22","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":45.5224,"value":227612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-26-000005","document":"form4-01262026_090133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000005/form4-01262026_090133.xml","form_type":"4"}},{"id":931299,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-26T16:10:37.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":true,"shares":2503,"price":10.42,"value":26081.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17965,"source":{"system":"sec-edgar","filing":"0002050422-26-000005","document":"form4-01262026_090133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000005/form4-01262026_090133.xml","form_type":"4"}},{"id":931298,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-26T16:10:37.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":true,"shares":2497,"price":10.42,"value":26018.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15462,"source":{"system":"sec-edgar","filing":"0002050422-26-000005","document":"form4-01262026_090133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000005/form4-01262026_090133.xml","form_type":"4"}},{"id":947389,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":4796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 1, 2025."}],"balance_after":2983,"derivative":{"exercise_price":10.42,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":4796},"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":947388,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":2377,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":204},"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":947387,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":2595,"price":39.5689,"value":102681.2955,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.99 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":947386,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":2405,"price":38.6995,"value":93072.2975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4."}],"balance_after":15560,"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":947385,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":4796,"price":10.42,"value":49974.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17965,"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":947384,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-01-06T16:30:29.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":204,"price":10.42,"value":2125.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":13169,"source":{"system":"sec-edgar","filing":"0002050422-26-000003","document":"form4-01062026_090124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042226000003/form4-01062026_090124.xml","form_type":"4"}},{"id":956678,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":2605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":2581,"derivative":{"exercise_price":10.42,"expiration_date":"2032-10-26","underlying":"Common Stock","underlying_shares":2605},"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956677,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":2395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025."}],"balance_after":1,"derivative":{"exercise_price":10.42,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":2395},"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956676,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":9876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":23834,"derivative":{"exercise_price":10.42,"expiration_date":"2034-04-23","underlying":"Common Stock","underlying_shares":9876},"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956675,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2025."}],"balance_after":2396,"derivative":{"exercise_price":10.42,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":124},"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956674,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":40.0814,"value":200407.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.36 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956673,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":2605,"price":10.42,"value":27144.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":17965,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956672,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":2395,"price":10.42,"value":24955.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":15360,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956671,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":600,"price":41.1583,"value":24694.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $41.29 per share, inclusive."}],"balance_after":12965,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956670,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":9400,"price":40.5395,"value":381071.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $40.94 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4."}],"balance_after":13565,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956669,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":9876,"price":10.42,"value":102907.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":22965,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":956668,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-12-31T16:20:07.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":124,"price":10.42,"value":1292.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."}],"balance_after":13089,"source":{"system":"sec-edgar","filing":"0002050422-25-000007","document":"form4-12312025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000007/form4-12312025_091203.xml","form_type":"4"}},{"id":1033236,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":54357,"kind":"person","name":"Bachrodt Amy","position":1,"cik":"0002050422","reported_name":"Bachrodt Amy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Restricted Stock Units","published_at":"2025-09-24T16:23:14.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":22000,"derivative":{"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0002050422-25-000004","document":"form4-09242025_080910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2050422/000205042225000004/form4-09242025_080910.xml","form_type":"4"}}]}